Share
Save
Pilot Study of MC in Paediatric Palliative Care
The goal of this pilot study is to explore the feasibility and acceptability of a medicinal cannabis clinical trial into easing the symptoms of children undergoing palliative care for non-oncological conditions. The trial will evaluate the study design including recruitment strategy, medication tolerability, duration and outcomes to determine acceptability and feasibility for participating families. The data collected will then be used to design a full-scale multi-centre trial.
Participants will be randomly allocated to receive one of two medicinal cannabis products. Neither the participants nor researchers will know the study drug allocation until the end of the trial.
Study details:
This is a single site, double-blind, randomized, pilot study of 10 participants investigating two medicinal cannabis (MC) products in children aged 6 months to 21 years who are undergoing palliative care for non-oncological conditions. Eligible participants will be randomized 1:1 to receive one of two medicinal cannabis products (C12T12 or C20T5). The primary objective of this pilot study is to evaluate all elements of the study design (recruitment strategy, study duration, study procedures, study medication tolerance and outcome measures) to assess if they are acceptable and feasible for the conduct of a full-scale randomised trial of MC to reduce symptom burden in paediatric patients undergoing palliative care for non-oncological conditions.
The secondary objective of this study is to collect preliminary data on the safety of two different oral MC oil formulations in this population. Each participants will be involved in the trial for up to 100 days:. * Screening period: Up to 14 days.
* Up-titration: day 1 to day 16. * Maintenance treatment period: day 17 to day 42. * Down-titration: day 43 (end of maintenance period clinic visit) to day 58.
* Post-treatment follow-up: day 59 to day 86.
Eligibility criteria
Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.
Inclusion criteria
Exclusion criteria
Eligibility
Age eligible for study : 6 and older
Healthy volunteers accepted : No
Gender eligible for study: All
Things to know
Study dates
Study start: 2024-02-19
Primary completion: 2024-12-01
Study completion finish: 2025-02-01
Study type
SUPPORTIVE_CARE
Phase
PHASE1
PHASE2
Trial ID
NCT05615389
Intervention or treatment
DRUG: Medicinal Cannabis - C12T12
DRUG: Medicinal Cannabis - C20T5
Conditions
- • Palliative Care
Find a site
Closest Location:
Royal Children's Hospital / Murdoch Children's Research Institute
Research sites nearby
Select from list below to view details:
Royal Children's Hospital / Murdoch Children's Research Institute
Parkville, Victoria, Australia
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
| Participant Group/Arm | Intervention/Treatment |
|---|---|
EXPERIMENTAL: Medicinal Cannabis C12T12
| DRUG: Medicinal Cannabis - C12T12
|
EXPERIMENTAL: Medicinal Cannabis C20T5
| DRUG: Medicinal Cannabis - C20T5
|
What is the study measuring?
Primary outcome
| Primary Outcome Measure | Primary Outcome Description | Primary Outcome Time Frame |
|---|---|---|
| Study participant recruitment completion time, calculated as the time required to reach a sample size of 10. | The time taken to complete recruitment will be calculated as the number of months from the date of commencing recruitment to the date of randomizing the tenth participant. | From the date of pre-screening the first participant until the tenth participant is randomized, up to 2 years. |
| Participant withdrawal rate, calculated as the number of participants who withdraw from the trial as a proportion of the total number of participants randomized. | The number of participants who withdraw from the trial will be calculated as a proportion of the total number of participants randomized. | Day 1 to day 43 (date of the end of the maintenance dosing period clinic visit) |
| Study medication tolerability, as indicated by the proportion of participants who tolerate the protocol dosing schedule. | The number of participants who adhere to the protocol dosing schedule without medication related protocol deviations, treatment discontinuations or dose modifications will be calculated as a proportion of the total sample for each arm (C12T12 and C20T5). | Day 1 to day 43 (date of the end of the maintenance dosing period clinic visit) |
| Participant adherence to the study medication dosing schedule, calculated as the proportion of participants who demonstrate acceptable medication compliance. | Medication compliance will be assessed through pharmacy calculations from returned bottle volumes. Acceptable compliance will fall within the range of 80-120%. The number of participants with acceptable medication compliance will be reported as a proportion of the total sample randomized. | Day 58 (date of end of treatment) |
| Study visit attendance, calculated as the proportion of visits completed across the study sample. | The number of study visits attended by all participants will be calculated as a proportion of the total possible visits in accordance with the study protocol. | Screening to day 43 (date of the end of the maintenance dosing period clinic visit) |
| Blood test completion, calculated as the proportion of blood tests completed across the study sample. | The number of study blood tests completed by all participants will be calculated as a proportion of the total possible blood tests in accordance with the study protocol. | Screening to day 43 (date of the end of the maintenance dosing period clinic visit) |
| Parent questionnaire completion, calculated as the proportion of parent-report questionnaires completed across the study sample. | The number of study questionnaires completed by all parents will be calculated as a proportion of the total possible questionnaires requiring completion in accordance with the study protocol. | Screening to day 86 (participant trial completion) |
| Self-report questionnaire completion, calculated as the proportion of adolescent self-report questionnaires completed across the study sample. | The number of study self-report questionnaires completed by all participants will be calculated as a proportion of the total possible questionnaires requiring completion in accordance with the study protocol. | Screening to day 86 (participant trial completion) |
| Study design acceptability will be evaluated through a parent-completed study specific evaluation questionnaire completed at the end of the study. | Study design acceptability will be assessed using an evaluation questionnaire developed specifically for this study, which uses Likert scales to assess satisfaction with recruitment, medication tolerability, frequency of study visits, burden of completing questionnaires, and overall study quality. Parents will complete this questionnaire at the end of their study participation (day 86). Data will be reported for each item individually, as the proportion of parents who responded positively on the Likert scale, where higher scores indicate more favorable responses. | Day 86 (participant trial completion) |
Secondary outcome
| Secondary Outcome Measure | Secondary Outcome Description | Secondary Outcome Time Frame |
|---|---|---|
| The frequency of adverse events as reported on the modified version of the Liverpool Adverse Event Profile (LAEP) at day 43 will be summarized across the two medicinal cannabis treatment arms. | Completed by the parent or guardian, the LAEP was designed to capture known side-effects of anti-epileptic medication. The modified version includes additional items to ascertain other known side-effects of medicinal cannabis. This measure includes 34 items. Adverse Events (AEs) reported on the LAEP will be considered significant if a 2-point increase in severity is reported from baseline to end of the maintenance dosing period (day 43). The frequency of AEs meeting this criteria will be presented for the two medicinal cannabis treatment arms respectively. | Day 43 (date of the end of the maintenance dosing period clinic visit) |
| The frequency of adverse events as reported throughout the study will be summarized across the two medicinal cannabis treatment arms. | All possible adverse events will be recorded, as reported at study visits, during safety check phone calls and in between scheduled appointments. All Serious Adverse Events will be published, as well as all non-serious adverse events deemed by the investigators to be at least possibly related to the study drug. The frequency of these adverse events will be presented for the two medicinal cannabis treatment arms respectively. | Day 1 to day 86 (participant trial completion) |
Frequently Asked Questions
Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol
No questions submitted. Be the first to ask a question!